Return to homepagePandemic Pact

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI148574-02S2

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2025

  • Known Financial Commitments (USD)

    $1,341,481

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Mark Joseph Mulligan

  • Research Location

    United States of America

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

PROJECT SUMMARY This supplement proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) research to be carried out at the NYU VTEU. We will participate in the implementation of in DMID protocol 21- 0012, "A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines." This Phase 1/2 study will evaluate the safety, tolerability, immunogenicity of different SARS-CoV-2 vaccine delayed boost at >12 weeks. This study will be composed of two different cohorts: 1. A cohort of persons previously vaccinated with an EUA vaccine who will be boosted with a homologous or heterologous vaccine strain on a homologous or a heterologous platform; and 2. A cohort of persons who are prospectively vaccinated with EUA standard dosing and who will be available for rapid assessment of a heterologous boost at some point in the future.